IFNA1 and congenital dyserythropoietic anemia: [6] Although the underlying mechanism remains unclear, a study by Wickramasinghe et al. revealed that CDA-I patients exhibit reduced IFN-α production compared with both healthy controls and patients with other CDA subtypes, possibly explaining its therapeutic benefit.